Drug firm Bajaj Healthcare on Tuesday announced the launch of its antiviral Favipiravir tablets under the brand name 'Favijaj' used for the treatment of mild to moderate Covid-19 infections in the country. The company has received approval from India's drug regulator DCGI to manufacture and market the tablets, Bajaj Healthcare said in a BSE filing."We hope the availability of an effective treatment such as Favijaj will considerably ease the pressure and offer patients much-needed and timely therapy options," Bajaj Healthcare Joint MD Anil Jain said.The company has successfully developed the active pharmaceutical ingredient (API) and the formulation for favipiravir through its own in-house R&D team, Bajaj Healthcare said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!